Medtech Insight is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Biopharma Quarterly Deal-making Statistics, Q4 2017

A look at financing, M&A and alliance activity October–December 2017

Executive Summary

Biopharma financing finished off 2017 strong with a total value of $14.5 billion in Q4, led again by FOPOs. CVS' massive $77 billion acquisition of Aetna resulted in an all-time quarterly high in the M&A category, and the largest alliances were dominated by the development of vaccines and antibodies.


Related Content

Expanded Access Data Supported Lutathera Approval, US FDA Notes
Roche Ramps Up Cancer Portfolio With $1.7bn Ignyta Buy
J&J Deal Helps Zymeworks Continue Transformational Year
Confirming Rumors, Novartis Buys AAA To Boost Oncology Business
$500m And Counting: Vir Puts Big Money To Work In Infectious Diseases
Lilly's Billion-Dollar Deal With CureVac For 'Next Generation' Immunotherapies
Consolidation in Generics Sector As Impax Merges With Amneal
Harmony Biosciences Raises $270m; Acquires US Rights To Narcolepsy Drug
Will Radiopharmaceutical Company AAA Be M&A Fodder For Novartis?
APOLLO Success Clears Alnylam For Lift-Off


Related Companies

Related Deals




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts